Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specific

被引：34

作者：

Stirewalt, DL

Willman, CL

Radich, JP

机构：

[1] Fred Hutchinson Canc Res Ctr, Div Clin Res, Program Genet & Genom, Seattle, WA 98109 USA

[2] Univ Washington, Div Oncol, Washington, DC USA

[3] SW Oncol Grp, Leukemia Biol Comm, San Antonio, TX 78245 USA

[4] Univ New Mexico, Sch Med, Dept Pathol & Cell Biol, Albuquerque, NM 87131 USA

来源：

LEUKEMIA RESEARCH | 2001年 / 25卷 / 12期

关键词：

leukemia; myeloid; FLT3; minimal residual disease;

D O I：

10.1016/S0145-2126(01)00087-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Internal tandem duplications (ITDs) of the FLT3 gene occur in approximate to 20-30% of acute myeloid leukemia (AML) patients. We investigated if FLT3 ITDs could be used as minimal residual disease (MRD) markers for AML patients. Patient-specific polymerase chain reaction (PCR) assays for FLT3 ITDs were developed for four AML samples that contained FLT3 ITDs of varying size and location. The real-time, quantitative PCR assays for FLT3 ITDs were highly sensitive and specific, detecting between 0.01 and 0.001% of FLT3 ITD positive DNA in a background of 1 mug of normal bone marrow DNA. Our findings suggest that FLT3 ITDs can be used as molecular markers for MRD in patients with AML. (C) 2001 Elsevier Science Ltd. All rights reserved.

引用

页码：1085 / 1088

页数：4

共 8 条

[1] OUTCOME PREDICTION IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA BY MOLECULAR QUANTIFICATION OF RESIDUAL DISEASE AT THE END OF INDUCTION
BRISCO, MJ
CONDON, J
HUGHES, E
NEOH, SH
SYKES, PJ
SESHADRI, R
TOOGOOD, I
WATERS, K
TAURO, G
EKERT, H
MORLEY, AA
[J]. LANCET, 1994, 343 (8891) : 196 - 200
[2] DASTUGUE N, 1995, LEUKEMIA, V9, P1491
[3] Kiyoi H, 1999, BLOOD, V93, P3074
[4] Molecular evolution of acute myeloid leukaemia in relapse:: unstable N-ras and FLT3 genes compared with p53 gene
Nakano, Y
Kiyoi, H
Miyawaki, S
Asou, N
Ohno, R
Saito, H
Naoe, T
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 1999, 104 (04) : 659 - 664
[5] Clinical applicability of the evaluation of minimal residual disease in acute leukemia
Radich, JP
[J]. CURRENT OPINION IN ONCOLOGY, 2000, 12 (01) : 36 - 40
[6] POLYMERASE CHAIN-REACTION DETECTION OF THE BCR-ABL FUSION TRANSCRIPT AFTER ALLOGENEIC MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA - RESULTS AND IMPLICATIONS IN 346 PATIENTS
RADICH, JP
GEHLY, G
GOOLEY, T
BRYANT, E
CLIFT, RA
COLLINS, S
EDMANDS, S
KIRK, J
LEE, A
KESSLER, P
SCHOCH, G
BUCKNER, CD
SULLIVAN, KM
APPELBAUM, FR
THOMAS, ED
[J]. BLOOD, 1995, 85 (09) : 2632 - 2638
[7] RAJYALAKSHMI L, 1998, AM J PATHOL, V153, P63
[8] FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia
Stirewalt, DL
Kopecky, KJ
Meshinchi, S
Appelbaum, FR
Slovak, ML
Willman, CL
Radich, JP
[J]. BLOOD, 2001, 97 (11) : 3589 - 3595

← 1 →